ANGLE plc’s Parsortix System Advances Cancer Research with New Studies

An announcement from ANGLE plc ( (GB:AGL) ) is now available.

ANGLE plc announced the publication of three peer-reviewed studies utilizing its Parsortix system to explore cancer biology and potential therapeutic targets. These studies highlight the system’s role in advancing understanding of tumor cell release during surgery and metastatic progression, offering insights that could guide future cancer treatment strategies. The findings underscore the potential of ANGLE’s technology to contribute to personalized cancer diagnostics and therapeutics, as academic and translational research continue to drive innovation in oncology.

The most recent analyst rating on (GB:AGL) stock is a Buy with a £70.00 price target. To see the full list of analyst forecasts on ANGLE plc stock, see the GB:AGL Stock Forecast page.

More about ANGLE plc

ANGLE plc is a leading company in the liquid biopsy industry, specializing in innovative circulating tumor cell (CTC) solutions for research, drug development, and clinical oncology. The company’s Parsortix PC1 System, which is FDA cleared and patent protected, allows for comprehensive downstream analysis of CTCs, including whole cell imaging, proteomic analysis, and full genomic and transcriptomic molecular analysis. ANGLE focuses on clinical services and diagnostic products, with services offered through GCLP-compliant laboratories.

Average Trading Volume: 1,329,130

Technical Sentiment Signal: Sell

Current Market Cap: £22.58M

See more insights into AGL stock on TipRanks’ Stock Analysis page.